Compare Procter & Gamble Co (PG) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Procter & Gamble Co vs Repligen Corporation Common Stock — how do they compare? Procter & Gamble Co trades at $157.15 (market cap $355.46B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Procter & Gamble Co is far larger — about 31.9× Repligen Corporation Common Stock's market cap, and Procter & Gamble Co pays a 2.85% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Procter & Gamble Co for 132 Days and Repligen Corporation Common Stock for 0 Days on average.
| PG | RGEN | |
|---|---|---|
Market Cap | $355.46B | $11.14B |
Volume | 5,731,171 | 1,259,263 |
Sector | Consumer Staples | Health |
52-Week High | $167.18 | $194.57 |
52-Week Low | $138.10 | $102.87 |
Typical Hold Time | 132 Days | 0 Days |
Enterprise Value | $381.30B | $11.02B |
Dividend Yield | 2.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Procter & Gamble (PG) trades at $156.57, up 2.2% today, near its consensus price target of $160.13. The stock shows bullish technical signals with strong moving average support and has beaten earnings estimates for three consecutive quarters. Revenue reached $84.28B in 2025 with a net income margin of 18.44%, while the company maintains a robust dividend history and positive cash flow trends.
PG offers stable growth with high profitability and shareholder returns, but premium valuation multiples pose near-term upside limitations. Risks include soft demand outlook and competitive pressures, though analyst consensus remains bullish with 53% buy ratings. The stock's resilience in volatile markets supports its appeal for dividend-focused investors.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
